Non-Alcoholic Steatohepatitis (NASH) Market Size, Share, and Outlook, H2-2025 Report- By Drug (Vitamin E & pioglitazone, Obeticholic Acid, Elafibranor, Selonsertib, Cenicriviroc), By Sales Channel (Hospital pharmacy, Online providers, Retail pharmacy) and
Description
Non-Alcoholic Steatohepatitis (NASH) Market Outlook
The global Non-Alcoholic Steatohepatitis (NASH) Market Size is valued at $8.1 Billion in 2025 and is forecast to reach $31.8 Billion in 2032 at a CAGR of 21.6%.
The Non-Alcoholic Steatohepatitis (NASH) Market continue to remain a steadily growing market and offers lucrative growth opportunities across the industry stakeholders from suppliers to distributors and end-use industries. This comprehensive market research report provides 12-year historic and forecast data on Non-Alcoholic Steatohepatitis (NASH) Market segments across 22 countries from 2021 to 2032. Key segments covered include By Drug (Vitamin E & pioglitazone, Obeticholic Acid, Elafibranor, Selonsertib, Cenicriviroc), By Sales Channel (Hospital pharmacy, Online providers, Retail pharmacy), offering granular insights into performance drivers and emerging patterns. With over 70 tables and charts, the report provides actionable findings based on extensive data modeling and industry surveys.
Non-Alcoholic Steatohepatitis (NASH) Market Insights, 2025
In the NASH therapeutics market, recent developments have focused on innovative drug candidates targeting key pathological processes such as inflammation, fibrosis, and metabolic dysregulation. Several late-stage clinical trials are evaluating novel anti-fibrotic agents and combination regimens to improve therapeutic outcomes. Biomarker research has advanced, improving diagnostic accuracy and patient selection for clinical trials, which has historically challenged drug development in this space. Regulatory pathways are evolving with an emphasis on non-invasive surrogate endpoints to facilitate accelerated approvals. Patient-centric digital tools are emerging to support lifestyle modification alongside pharmacotherapy. Additionally, real-world data collection is helping to understand treatment patterns and outcomes outside clinical trial settings. Collaborations between biopharma companies and academic research centers are accelerating discovery and validation of novel targets. The market is also observing increased focus on co-morbidities such as diabetes and cardiovascular disease, influencing drug development strategies.
Five Trends Shaping the Global Non-Alcoholic Steatohepatitis (NASH) Market in 2025 and Beyond
The global Non-Alcoholic Steatohepatitis (NASH) Industry is undergoing a paradigm shift driven by regulatory changes, technological innovation, and sustainability imperatives. Amidst intense demand growth from diverse end-users, companies are focusing on new product launches to cater to individual applications. Companies are also emphasizing operational resilience and circular economy principles and are aligning strategies to secure long-term growth. The report identifies key structural changes, disruptive technologies, and evolving trade flows influencing competitiveness, helping stakeholders strengthen decision-making for both the short and long term.
What are the Biggest Opportunities for Growth in the Non-Alcoholic Steatohepatitis (NASH) Industry?
The Non-Alcoholic Steatohepatitis (NASH) Market sector has shown strong adaptability amid volatility in prices, supply chain disruptions, and geopolitical tensions. Moving forward, potential opportunities lie in niche products, aggressive distribution activities, and digital process optimization. With increasing demand from emerging markets, Non-Alcoholic Steatohepatitis (NASH) Market is positioned for growth through 2030 and beyond. This chapter provides a strategic perspective for businesses to identify revenue-generating avenues, mitigate risks, and adopt innovative pathways for expansion.
Non-Alcoholic Steatohepatitis (NASH) Market Segment Insights
The Non-Alcoholic Steatohepatitis (NASH) Industry offers diverse opportunities across product types, applications, and distribution channels. The analytical report provides detailed forecasts across diverse segments including By Drug (Vitamin E & pioglitazone, Obeticholic Acid, Elafibranor, Selonsertib, Cenicriviroc), By Sales Channel (Hospital pharmacy, Online providers, Retail pharmacy). Insights cover the largest and fastest-growing product types, applications, and regions, highlighting drivers behind each segment. Market outlooks are provided for five regions—Asia Pacific, North America, Europe, South America, and Middle East & Africa—with country-level forecasts for 22 markets through 2032.
Non-Alcoholic Steatohepatitis (NASH) Industry Value Chain
The chapter identifies potential companies and their operations across the global Non-Alcoholic Steatohepatitis (NASH) Industry ecosystem. It assists decision-makers in evaluating global Non-Alcoholic Steatohepatitis (NASH) Market fundamentals, market dynamics, and disruptive trends across the value chain segments. According to the International Council of Chemical Associations (ICCA), chemicals underpin over 95% of manufactured products worldwide.
Scenario Analysis and Forecasts
Strategic planning in the Non-Alcoholic Steatohepatitis (NASH) Industry requires resilience to uncertain macroeconomic and regulatory conditions. To guide stakeholders, the report offers three scenario forecasts—low growth, reference case, and high growth—enabling companies to align strategies under different market conditions.
Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Market Analysis – Hub of Industrial Transformation
Asia Pacific continues to be the largest and fastest-growing region for Non-Alcoholic Steatohepatitis (NASH) Market, underpinned by rapid industrialization, large-scale infrastructure development, and rising consumption across emerging economies. China, India, and Southeast Asia lead the demand surge, supported by investments in chemical parks, free trade agreements, and rising domestic manufacturing capacity. China remains the single largest producer and consumer of chemicals, accounting for over $1.5 trillion in chemical sales, followed by India, which is projected by the India Brand Equity Foundation (IBEF) to become a $300 billion chemicals market by 2025. Further, Japanese and South Korean markets remain stable with most companies focusing on new product launches and diversification of sales channels.
United States Non-Alcoholic Steatohepatitis (NASH) Market Insights – Innovation and Specialty Leadership
The American Chemistry Council (ACC) projects steady annual demand growth for specialty and performance chemicals, particularly in automotive, electronics, agriculture, and construction applications. The US continues to lead in specialty and high-value-added chemicals, with investments focused on R&D, advanced process technologies, and digital manufacturing. In addition, the Canadian and Mexican markets offer lucrative growth pockets for manufacturers and vendors. Focus on private-brand offerings and promotions, diversified sales channels, expansion into niche segments, adoption of advanced technologies, and sustainability are widely observed across the North American Non-Alcoholic Steatohepatitis (NASH) Market.
Europe Non-Alcoholic Steatohepatitis (NASH) Market Outlook 2025 – Regulatory and Innovation-Driven Growth
Europe is one of the largest markets for Non-Alcoholic Steatohepatitis (NASH) Market with demand from both Western Europe and Eastern European regions increasing over the medium to long-term future. The European chemical sector employs more than 1.2 million people directly and is highly influenced by the EU Green Deal, which aims for climate neutrality by 2050. With increasing adoption of advanced technologies, raw materials, and digital transformation, Europe remains a strategic hub for Non-Alcoholic Steatohepatitis (NASH) Industry competitiveness. The report analyses the key Non-Alcoholic Steatohepatitis (NASH) Market drivers and opportunities across Germany, France, the United Kingdom, Spain, Italy, Russia, and other Europe.
Latin American Non-Alcoholic Steatohepatitis (NASH) Market outlook rebounds in line with economic growth
Optimistic economic outlook across Brazil, Argentina, Chile, and other South and Central American countries presents strong opportunities for domestic and international Non-Alcoholic Steatohepatitis (NASH) Market companies. Increased consumer spending is estimated across markets over the next few quarters through 2026. Expanding trade partnerships, urbanization, and growing demand for specialty products underpin market prospects.
Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Markets- New Opportunities for Companies Harnessing Diversity
The Middle East remains a key hub for Non-Alcoholic Steatohepatitis (NASH) Market companies, with Saudi Arabia, UAE, and Qatar investing heavily in distribution networks. In addition, Africa presents strong growth potential in Nigeria, South Africa, and other emerging economies, with increasing demand for cost effective and accessible products. Investment strategies tailored to localized needs and sustainable growth will be crucial for success. In addition to Nigeria, Algeria, South Africa, and other markets, steady growth markets in Ethiopia, Rwanda, Ghana, Tanzania, the Democratic Republic of Congo, and others present significant prospects for companies.
Competitive Landscape – How Non-Alcoholic Steatohepatitis (NASH) Market Companies Outcompete in 2025
The ability to adapt to changing regulations, sustainability imperatives, and customer-specific innovations defines leadership in the Non-Alcoholic Steatohepatitis (NASH) Market. Companies are leveraging M&A activities, strategic joint ventures, and vertical integration to secure raw material access and strengthen downstream presence. The report profiles leading players, analyzing their 2024 revenues, market shares, R&D expenditures, and strategic directions. The report analyzes AstraZeneca Plc, BioPredictive S.A.S, Cirius Therapeutics, Enzo Biochem Inc, GENFIT SA, Gilead Sciences Inc, GlaxoSmithKline Plc, Intercept Pharmaceuticals Inc, Inventiva S.A., Madrigal Pharmaceuticals Inc, Novo Nordisk AS, Prometheus Laboratories, Siemens Healthineers AG. Each company is benchmarked through a detailed SWOT and financial analysis, providing clients with insights into competitive positioning and innovation leadership.
Non-Alcoholic Steatohepatitis (NASH) Market Scope
Leading Segments
By Drug
Vitamin E & pioglitazone
Obeticholic Acid
Elafibranor
Selonsertib
Cenicriviroc
By Sales Channel
Hospital pharmacy
Online providers
Retail pharmacy
Leading Companies
AstraZeneca Plc
BioPredictive S.A.S
Cirius Therapeutics
Enzo Biochem Inc
GENFIT SA
Gilead Sciences Inc
GlaxoSmithKline Plc
Intercept Pharmaceuticals Inc
Inventiva S.A.
Madrigal Pharmaceuticals Inc
Novo Nordisk AS
Prometheus Laboratories
Siemens Healthineers AG
Geographies
North America- US, Canada, Mexico
Europe- Germany, France, UK, Spain, Italy, Nordics, BeNeLux, Others
Asia Pacific- China, India, Japan, South Korea, Australia, South East Asia, Others
Latin America- Brazil, Argentina, Others
Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa
Reasons to Buy the Report Make informed decisions with 12-year forecasts across 22 countries and multiple market segments. Evaluate regulatory impacts, sustainability trends, and disruptive technologies shaping the chemicals industry. Gain insights into the competitive landscape, including company profiles, financials, and strategic moves. Build an integrated understanding of the chemicals ecosystem across upstream, midstream, and downstream operations. Leverage insights on circular economy initiatives, digitalization, and carbon-neutral strategies driving the next decade. Assess risks and opportunities with scenario-based forecasts tailored to different growth conditions. Access the report in multiple formats (PDF, Excel, PPT) for easier integration into strategic planning.
The global Non-Alcoholic Steatohepatitis (NASH) Market Size is valued at $8.1 Billion in 2025 and is forecast to reach $31.8 Billion in 2032 at a CAGR of 21.6%.
The Non-Alcoholic Steatohepatitis (NASH) Market continue to remain a steadily growing market and offers lucrative growth opportunities across the industry stakeholders from suppliers to distributors and end-use industries. This comprehensive market research report provides 12-year historic and forecast data on Non-Alcoholic Steatohepatitis (NASH) Market segments across 22 countries from 2021 to 2032. Key segments covered include By Drug (Vitamin E & pioglitazone, Obeticholic Acid, Elafibranor, Selonsertib, Cenicriviroc), By Sales Channel (Hospital pharmacy, Online providers, Retail pharmacy), offering granular insights into performance drivers and emerging patterns. With over 70 tables and charts, the report provides actionable findings based on extensive data modeling and industry surveys.
Non-Alcoholic Steatohepatitis (NASH) Market Insights, 2025
In the NASH therapeutics market, recent developments have focused on innovative drug candidates targeting key pathological processes such as inflammation, fibrosis, and metabolic dysregulation. Several late-stage clinical trials are evaluating novel anti-fibrotic agents and combination regimens to improve therapeutic outcomes. Biomarker research has advanced, improving diagnostic accuracy and patient selection for clinical trials, which has historically challenged drug development in this space. Regulatory pathways are evolving with an emphasis on non-invasive surrogate endpoints to facilitate accelerated approvals. Patient-centric digital tools are emerging to support lifestyle modification alongside pharmacotherapy. Additionally, real-world data collection is helping to understand treatment patterns and outcomes outside clinical trial settings. Collaborations between biopharma companies and academic research centers are accelerating discovery and validation of novel targets. The market is also observing increased focus on co-morbidities such as diabetes and cardiovascular disease, influencing drug development strategies.
Five Trends Shaping the Global Non-Alcoholic Steatohepatitis (NASH) Market in 2025 and Beyond
The global Non-Alcoholic Steatohepatitis (NASH) Industry is undergoing a paradigm shift driven by regulatory changes, technological innovation, and sustainability imperatives. Amidst intense demand growth from diverse end-users, companies are focusing on new product launches to cater to individual applications. Companies are also emphasizing operational resilience and circular economy principles and are aligning strategies to secure long-term growth. The report identifies key structural changes, disruptive technologies, and evolving trade flows influencing competitiveness, helping stakeholders strengthen decision-making for both the short and long term.
What are the Biggest Opportunities for Growth in the Non-Alcoholic Steatohepatitis (NASH) Industry?
The Non-Alcoholic Steatohepatitis (NASH) Market sector has shown strong adaptability amid volatility in prices, supply chain disruptions, and geopolitical tensions. Moving forward, potential opportunities lie in niche products, aggressive distribution activities, and digital process optimization. With increasing demand from emerging markets, Non-Alcoholic Steatohepatitis (NASH) Market is positioned for growth through 2030 and beyond. This chapter provides a strategic perspective for businesses to identify revenue-generating avenues, mitigate risks, and adopt innovative pathways for expansion.
Non-Alcoholic Steatohepatitis (NASH) Market Segment Insights
The Non-Alcoholic Steatohepatitis (NASH) Industry offers diverse opportunities across product types, applications, and distribution channels. The analytical report provides detailed forecasts across diverse segments including By Drug (Vitamin E & pioglitazone, Obeticholic Acid, Elafibranor, Selonsertib, Cenicriviroc), By Sales Channel (Hospital pharmacy, Online providers, Retail pharmacy). Insights cover the largest and fastest-growing product types, applications, and regions, highlighting drivers behind each segment. Market outlooks are provided for five regions—Asia Pacific, North America, Europe, South America, and Middle East & Africa—with country-level forecasts for 22 markets through 2032.
Non-Alcoholic Steatohepatitis (NASH) Industry Value Chain
The chapter identifies potential companies and their operations across the global Non-Alcoholic Steatohepatitis (NASH) Industry ecosystem. It assists decision-makers in evaluating global Non-Alcoholic Steatohepatitis (NASH) Market fundamentals, market dynamics, and disruptive trends across the value chain segments. According to the International Council of Chemical Associations (ICCA), chemicals underpin over 95% of manufactured products worldwide.
Scenario Analysis and Forecasts
Strategic planning in the Non-Alcoholic Steatohepatitis (NASH) Industry requires resilience to uncertain macroeconomic and regulatory conditions. To guide stakeholders, the report offers three scenario forecasts—low growth, reference case, and high growth—enabling companies to align strategies under different market conditions.
Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Market Analysis – Hub of Industrial Transformation
Asia Pacific continues to be the largest and fastest-growing region for Non-Alcoholic Steatohepatitis (NASH) Market, underpinned by rapid industrialization, large-scale infrastructure development, and rising consumption across emerging economies. China, India, and Southeast Asia lead the demand surge, supported by investments in chemical parks, free trade agreements, and rising domestic manufacturing capacity. China remains the single largest producer and consumer of chemicals, accounting for over $1.5 trillion in chemical sales, followed by India, which is projected by the India Brand Equity Foundation (IBEF) to become a $300 billion chemicals market by 2025. Further, Japanese and South Korean markets remain stable with most companies focusing on new product launches and diversification of sales channels.
United States Non-Alcoholic Steatohepatitis (NASH) Market Insights – Innovation and Specialty Leadership
The American Chemistry Council (ACC) projects steady annual demand growth for specialty and performance chemicals, particularly in automotive, electronics, agriculture, and construction applications. The US continues to lead in specialty and high-value-added chemicals, with investments focused on R&D, advanced process technologies, and digital manufacturing. In addition, the Canadian and Mexican markets offer lucrative growth pockets for manufacturers and vendors. Focus on private-brand offerings and promotions, diversified sales channels, expansion into niche segments, adoption of advanced technologies, and sustainability are widely observed across the North American Non-Alcoholic Steatohepatitis (NASH) Market.
Europe Non-Alcoholic Steatohepatitis (NASH) Market Outlook 2025 – Regulatory and Innovation-Driven Growth
Europe is one of the largest markets for Non-Alcoholic Steatohepatitis (NASH) Market with demand from both Western Europe and Eastern European regions increasing over the medium to long-term future. The European chemical sector employs more than 1.2 million people directly and is highly influenced by the EU Green Deal, which aims for climate neutrality by 2050. With increasing adoption of advanced technologies, raw materials, and digital transformation, Europe remains a strategic hub for Non-Alcoholic Steatohepatitis (NASH) Industry competitiveness. The report analyses the key Non-Alcoholic Steatohepatitis (NASH) Market drivers and opportunities across Germany, France, the United Kingdom, Spain, Italy, Russia, and other Europe.
Latin American Non-Alcoholic Steatohepatitis (NASH) Market outlook rebounds in line with economic growth
Optimistic economic outlook across Brazil, Argentina, Chile, and other South and Central American countries presents strong opportunities for domestic and international Non-Alcoholic Steatohepatitis (NASH) Market companies. Increased consumer spending is estimated across markets over the next few quarters through 2026. Expanding trade partnerships, urbanization, and growing demand for specialty products underpin market prospects.
Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Markets- New Opportunities for Companies Harnessing Diversity
The Middle East remains a key hub for Non-Alcoholic Steatohepatitis (NASH) Market companies, with Saudi Arabia, UAE, and Qatar investing heavily in distribution networks. In addition, Africa presents strong growth potential in Nigeria, South Africa, and other emerging economies, with increasing demand for cost effective and accessible products. Investment strategies tailored to localized needs and sustainable growth will be crucial for success. In addition to Nigeria, Algeria, South Africa, and other markets, steady growth markets in Ethiopia, Rwanda, Ghana, Tanzania, the Democratic Republic of Congo, and others present significant prospects for companies.
Competitive Landscape – How Non-Alcoholic Steatohepatitis (NASH) Market Companies Outcompete in 2025
The ability to adapt to changing regulations, sustainability imperatives, and customer-specific innovations defines leadership in the Non-Alcoholic Steatohepatitis (NASH) Market. Companies are leveraging M&A activities, strategic joint ventures, and vertical integration to secure raw material access and strengthen downstream presence. The report profiles leading players, analyzing their 2024 revenues, market shares, R&D expenditures, and strategic directions. The report analyzes AstraZeneca Plc, BioPredictive S.A.S, Cirius Therapeutics, Enzo Biochem Inc, GENFIT SA, Gilead Sciences Inc, GlaxoSmithKline Plc, Intercept Pharmaceuticals Inc, Inventiva S.A., Madrigal Pharmaceuticals Inc, Novo Nordisk AS, Prometheus Laboratories, Siemens Healthineers AG. Each company is benchmarked through a detailed SWOT and financial analysis, providing clients with insights into competitive positioning and innovation leadership.
Non-Alcoholic Steatohepatitis (NASH) Market Scope
Leading Segments
By Drug
Vitamin E & pioglitazone
Obeticholic Acid
Elafibranor
Selonsertib
Cenicriviroc
By Sales Channel
Hospital pharmacy
Online providers
Retail pharmacy
Leading Companies
AstraZeneca Plc
BioPredictive S.A.S
Cirius Therapeutics
Enzo Biochem Inc
GENFIT SA
Gilead Sciences Inc
GlaxoSmithKline Plc
Intercept Pharmaceuticals Inc
Inventiva S.A.
Madrigal Pharmaceuticals Inc
Novo Nordisk AS
Prometheus Laboratories
Siemens Healthineers AG
Geographies
North America- US, Canada, Mexico
Europe- Germany, France, UK, Spain, Italy, Nordics, BeNeLux, Others
Asia Pacific- China, India, Japan, South Korea, Australia, South East Asia, Others
Latin America- Brazil, Argentina, Others
Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa
Reasons to Buy the Report
Table of Contents
194 Pages
- 1. Table of Contents
- List of Figures and Tables
- 2. Executive Summary
- 2.1 Key Highlights
- 2.1.1 Non-Alcoholic Steatohepatitis (NASH) Market Size Outlook, 2018-2024 and 2025-2032
- 2.1.2 Largest Non-Alcoholic Steatohepatitis (NASH) Market Types and Applications
- 2.1.3 Fastest Growing Segments
- 2.1.4 Potential Markets
- 2.1.5 Market Concentration
- 2.2 Market Scope and Segmentation
- 2.2.1 Market Scope- Segments
- 2.2.2 Market Scope- Countries
- 2.2.3 Macroeconomic and Demographic Outlook
- 2.2.4 Abbreviations
- 2.2.5 Units and Currency Conversions
- 3. Research Methodology
- 3.1 Primary Research Surveys
- 3.2 Secondary Data Sources
- 3.3 Data Triangulation
- 3.4 Forecast Methodology
- 3.5 Assumptions and Limitations
- 4. Introduction to Global Non-Alcoholic Steatohepatitis (NASH) Market in 2025
- 4.1 Industry Panorama
- 4.2 Leading Companies Profiled in the Study
- 4.3 Asia Pacific Markets offer Robust Market Prospects for New Entrants
- 4.4 Market Dynamics
- 4.4.1 Market Dynamics- Trends and Drivers
- 4.4.2 Market Dynamics- Opportunities and Challenges
- 4.5 Regional Analysis
- 4.6 Porter’s Five Force Analysis
- 4.6.1 Intensity of Competitive Rivalry
- 4.6.2 Threat of New Entrants
- 4.6.3 Threat of Substitutes
- 4.6.4 Bargaining Power of Buyers
- 4.6.5 Bargaining Power of Suppliers
- 4.7 Non-Alcoholic Steatohepatitis (NASH) Market Industry Value Chain Analysis
- 4.7.1 Stage of Value Chain
- 4.7.2 Key Activities of Companies
- 4.7.3 Companies Included in Each Stage
- 4.7.4 Key Insights
- 5. Non-Alcoholic Steatohepatitis (NASH) Market Outlook to 2032
- 5.1 Market Size Forecast by Type, 2021-2024 and 2025-2032
- 5.2 Market Size Forecast by Application, 2021-2024 and 2024-2032
- 5.3 Market Size Forecast by Geography, 2021-2024 and 2024-2032
- By Drug
- Vitamin E & pioglitazone
- Obeticholic Acid
- Elafibranor
- Selonsertib
- Cenicriviroc
- By Sales Channel
- Hospital pharmacy
- Online providers
- Retail pharmacy
- 6. Global Non-Alcoholic Steatohepatitis (NASH) Market Outlook across Growth Scenarios
- 6.1 Low Growth Scenario
- 6.2 Base/Reference Case
- 6.3 High Growth Scenario
- 6. North America Non-Alcoholic Steatohepatitis (NASH) Market Size Outlook
- 6.1 Key Market Statistics, 2024
- 6.2 North America Non-Alcoholic Steatohepatitis (NASH) Market Trends and Growth Opportunities
- 6.2.1 North America Non-Alcoholic Steatohepatitis (NASH) Market Outlook by Type
- 6.2.2 North America Non-Alcoholic Steatohepatitis (NASH) Market Outlook by Application
- 6.3 North America Non-Alcoholic Steatohepatitis (NASH) Market Outlook by Country
- 6.3.1 The US Non-Alcoholic Steatohepatitis (NASH) Market Outlook, 2021- 2032
- 6.3.2 Canada Non-Alcoholic Steatohepatitis (NASH) Market Outlook, 2021- 2032
- 6.3.3 Mexico Non-Alcoholic Steatohepatitis (NASH) Market Outlook, 2021- 2032
- 7. Europe Non-Alcoholic Steatohepatitis (NASH) Market Size Outlook
- 7.1 Key Market Statistics, 2024
- 7.2 Europe Non-Alcoholic Steatohepatitis (NASH) Market Trends and Growth Opportunities
- 7.2.1 Europe Non-Alcoholic Steatohepatitis (NASH) Market Outlook by Type
- 7.2.2 Europe Non-Alcoholic Steatohepatitis (NASH) Market Outlook by Application
- 7.3 Europe Non-Alcoholic Steatohepatitis (NASH) Market Outlook by Country
- 7.3.2 Germany Non-Alcoholic Steatohepatitis (NASH) Market Outlook, 2021- 2032
- 7.3.3 France Non-Alcoholic Steatohepatitis (NASH) Market Outlook, 2021- 2032
- 7.3.4 The UK Non-Alcoholic Steatohepatitis (NASH) Market Outlook, 2021- 2032
- 7.3.5 Spain Non-Alcoholic Steatohepatitis (NASH) Market Outlook, 2021- 2032
- 7.3.6 Italy Non-Alcoholic Steatohepatitis (NASH) Market Outlook, 2021- 2032
- 7.3.7 Russia Non-Alcoholic Steatohepatitis (NASH) Market Outlook, 2021- 2032
- 7.3.8 Rest of Europe Non-Alcoholic Steatohepatitis (NASH) Market Outlook, 2021- 2032
- 8. Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Market Size Outlook
- 8.1 Key Market Statistics, 2024
- 8.2 Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Market Trends and Growth Opportunities
- 8.2.1 Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Market Outlook by Type
- 8.2.2 Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Market Outlook by Application
- 8.3 Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Market Outlook by Country
- 8.3.1 China Non-Alcoholic Steatohepatitis (NASH) Market Outlook, 2021- 2032
- 8.3.2 India Non-Alcoholic Steatohepatitis (NASH) Market Outlook, 2021- 2032
- 8.3.3 Japan Non-Alcoholic Steatohepatitis (NASH) Market Outlook, 2021- 2032
- 8.3.4 South Korea Non-Alcoholic Steatohepatitis (NASH) Market Outlook, 2021- 2032
- 8.3.5 Australia Non-Alcoholic Steatohepatitis (NASH) Market Outlook, 2021- 2032
- 8.3.6 South East Asia Non-Alcoholic Steatohepatitis (NASH) Market Outlook, 2021- 2032
- 8.3.7 Rest of Asia Pacific Non-Alcoholic Steatohepatitis (NASH) Market Outlook, 2021- 2032
- 9. South America Non-Alcoholic Steatohepatitis (NASH) Market Size Outlook
- 9.1 Key Market Statistics, 2024
- 9.2 South America Non-Alcoholic Steatohepatitis (NASH) Market Trends and Growth Opportunities
- 9.2.1 South America Non-Alcoholic Steatohepatitis (NASH) Market Outlook by Type
- 9.2.2 South America Non-Alcoholic Steatohepatitis (NASH) Market Outlook by Application
- 9.3 South America Non-Alcoholic Steatohepatitis (NASH) Market Outlook by Country
- 9.3.1 Brazil Non-Alcoholic Steatohepatitis (NASH) Market Outlook, 2021- 2032
- 9.3.2 Argentina Non-Alcoholic Steatohepatitis (NASH) Market Outlook, 2021- 2032
- 9.3.3 Rest of South and Central America Non-Alcoholic Steatohepatitis (NASH) Market Outlook, 2021- 2032
- 10. Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Market Size Outlook
- 10.1 Key Market Statistics, 2024
- 10.2 Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Market Trends and Growth Opportunities
- 10.2.1 Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Market Outlook by Type
- 10.2.2 Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Market Outlook by Application
- 10.3 Middle East and Africa Non-Alcoholic Steatohepatitis (NASH) Market Outlook by Country
- 10.3.1 Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Market Outlook, 2021- 2032
- 10.3.2 The UAE Non-Alcoholic Steatohepatitis (NASH) Market Outlook, 2021- 2032
- 10.3.3 Rest of Middle East Non-Alcoholic Steatohepatitis (NASH) Market Outlook, 2021- 2032
- 10.3.4 South Africa Non-Alcoholic Steatohepatitis (NASH) Market Outlook, 2021- 2032
- 10.3.5 Egypt Non-Alcoholic Steatohepatitis (NASH) Market Outlook, 2021- 2032
- 10.3.6 Rest of Africa Non-Alcoholic Steatohepatitis (NASH) Market Outlook, 2021- 2032
- 11. Company Profiles
- 11.1 Leading 10 Companies
- AstraZeneca Plc
- BioPredictive S.A.S
- Cirius Therapeutics
- Enzo Biochem Inc
- GENFIT SA
- Gilead Sciences Inc
- GlaxoSmithKline Plc
- Intercept Pharmaceuticals Inc
- Inventiva S.A.
- Madrigal Pharmaceuticals Inc
- Novo Nordisk AS
- Prometheus Laboratories
- Siemens Healthineers AG
- 11.2 Overview
- 11.3 Products and Services
- 11.4 SWOT Profile
- 12. Appendix
- 12.1 Subscription Options
- 12.2 Customization Options
- 12.3 Publisher Details
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
